Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Reduced left ventricular ejection fraction and Enlarged and weakened heart (dilated cardiomyopathy); and common findings: Second degree atrioventricular block and Congestive heart failure. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 6 | Second degree atrioventricular block, Premature ventricular contraction, Congestive heart failure |
VEZF1 function has not been fully characterized.
Cardiomyopathy, dilated, 100 is associated with mutations in the VEZF1 gene on chromosome 17.
Genetic testing for VEZF1 is available. Testing is considered unknown for diagnosis.
Biomarker and diagnostic research for cardiomyopathy, dilated, 100 has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 2 common features.
No clinical trials have been registered for cardiomyopathy, dilated, 100.
96 publications have been identified in PubMed for cardiomyopathy, dilated, 100. Research spans Epidemiology / Natural History (31%), Review / Meta-Analysis (22%), and Basic Science / Preclinical (21%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 24 | 31% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 4:29 PM UTC
Online Mendelian Inheritance in Man
Common questions about cardiomyopathy, dilated, 100
Research summaries
17 |
22% |
Laboratory research | 16 | 21% |
Testing and diagnosis research | 12 | 15% |
Clinical study results | 4 | 5% |
New treatment approaches | 3 | 4% |
Patient case studies | 2 | 3% |
Nunes MCP (2026). [PMID: 41879141](https://pubmed.ncbi.nlm.nih.gov/41879141/). *Eur Heart J*. [Review / Meta-Analysis]
Ghaithan S (2026). [PMID: 41862809](https://pubmed.ncbi.nlm.nih.gov/41862809/). *BMC Cardiovasc Disord*. [Diagnostic / Biomarker]
Abdul Jabbar AB (2026). [PMID: 41473958](https://pubmed.ncbi.nlm.nih.gov/41473958/). *Circ Heart Fail*. [Epidemiology / Natural History]
Liu N (2026). [PMID: 40884535](https://pubmed.ncbi.nlm.nih.gov/40884535/). *J Magn Reson Imaging*. [Epidemiology / Natural History]
Bestetti RB (2026). [PMID: 41711721](https://pubmed.ncbi.nlm.nih.gov/41711721/). *ESC Heart Fail*. [Gene Therapy / Novel Therapeutics]
Romito G (2026). [PMID: 41669194](https://pubmed.ncbi.nlm.nih.gov/41669194/). *Front Vet Sci*. [Clinical Trial Publication]
Nguyen TM (2026). [PMID: 41955288](https://pubmed.ncbi.nlm.nih.gov/41955288/). *Europace*. [Gene Therapy / Novel Therapeutics]
Ajufo E (2026). [PMID: 41205222](https://pubmed.ncbi.nlm.nih.gov/41205222/). *JAMA cardiology*. [Epidemiology / Natural History]
Verdonschot JAJ (2026). [PMID: 41858107](https://pubmed.ncbi.nlm.nih.gov/41858107/). *European heart journal*. [Epidemiology / Natural History]
Isohanni P (2026). [PMID: 41932149](https://pubmed.ncbi.nlm.nih.gov/41932149/). *J Neurol Sci*. [Epidemiology / Natural History]